Current and Emerging CAR T-Cell Therapies in Cancer Care

Download All
Hear from the experts on how the latest clinical data inform the use of CAR T-cell therapies across hematologic malignancies. Review their insights with an on-demand webcast adapted from a live webinar, along with downloadable slidesets, 2 expert commentaries, and a podcast.
Caron A. Jacobson, MD
Noopur Raje, MD


The approval of the BCMA-targeted CAR T-cell therapy idecabtagene vicleucel provides another treatment option for some patients with relapsed/refractory multiple myeloma. Review this expert commentary on how to incorporate this therapeutic agent into your practice.

Noopur Raje, MD Released: June 2, 2021

CAR T-cell therapies can meaningfully improve outcomes for patients with certain hematologic cancers, but these treatments can cause a unique spectrum of adverse events to which physicians must be attuned. In this commentary, an expert describes key considerations in managing delayed toxicities associated with CAR T-cell therapy, including cytopenias and infections.

Caron A. Jacobson, MD Released: August 5, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bristol-Myers Squibb

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings